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A B S T R A C T
Novel developments in biomarkers discovery are essential in modern health care, notably in treatment
individualization and precision medicine. Clinical metabolomics, which aims to identify small molecule
metabolites present in patient-derived samples, has attracted much attention to support discovery of novel
biomarkers. However, the step from discriminatory features of disease states towards biomarkers that can truly
individualize treatments is challenging. Biomarkers used for treatment individualization can either be dynamic
or static prognostic biomarkers. Dynamic biomarkers are relevant for describing the clinical response, including
dynamical disease progression and associated treatment response. Static (prognostic) biomarkers do not describe
but rather predict a clinical response, and typically reflect aspects of the physiological state of a patient related to
drug treatment response or disease progression dynamics. Pharmacokinetic-pharmacodynamic (PK-PD) model-
ing represents an established approach for drug treatment individualization based on drug exposure or treatment
response biomarkers, as well as for the description of disease progression dynamics. Here, we discuss how novel
treatment individualization biomarkers can be identified using a clinical metabolomics-based approach, and
how concepts inspired from the field of PK-PD modeling can be integrated in this process in order to increase the
clinical relevance of identified biomarkers and precision medicine.
1. Introduction
Biomarkers have been defined as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic
intervention“(Biomarkers Definitions Working Group 2001). Biomar-
kers form the cornerstone of treatment individualization and precision
medicine. Here, treatment individualization biomarkers should not only
inform the choice of the best drug for each patient, but, equally
important, the optimal individualized choice of dose regimen. In this
context, we emphasize the important distinction between dynamic and
static biomarkers, illustrated in Fig. 1. Dynamic biomarkers describe
disease progression and associated treatment response (Fig. 1), and are
widely used in patient care and drug development. Examples are
prostate specific antigen dynamics for prostate cancer treatment
response (van Hasselt et al. 2015), or neutrophil count dynamics to
monitor drug-induced hematological toxicity (van Hasselt et al. 2013).
Static biomarkers are prognostic and aim to predict a clinical response
or a dynamical biomarker thereof (Fig. 1). Examples include gene
expression signatures to predict clinical benefit of anti-cancer drugs
(Cardoso et al. 2016) or the prediction of risk of cardiac function
declines after trastuzumab treatment (van Hasselt et al. 2011).
Mathematical pharmacokinetic-pharmacodynamic (PK-PD) model-
ing has developed into an established quantitative approach to support
both drug development and clinical treatment individualization
(Knibbe and Danhof 2011; Van Hasselt et al., 2014a; Van Hasselt
et al., 2014b). PK-PD modeling uses biomarkers for drug exposure and
their relation with drug effects and disease progression, as well as their
explicit consideration of the dynamics and inter-individual variation
(Danhof et al. 2005). The field of PK-PD has now co-evolved together
with the increasing biochemical characterization of disease and drug
response to the emerging area of quantitative systems pharmacology
(QSP) modeling (Danhof 2016; Danhof et al. 2008; van der Graaf and
Benson 2011; van Hasselt and van der Graaf 2015).
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Current clinical practice relies on a limited selection of diagnostic
molecular biomarkers to predict or monitor the response to a treatment
in individual patients. The majority of these biomarkers have been
identified decades ago, even though for many indications adequate
biomarkers are missing. For instance, clinical biomarkers for pain are
still lacking (Goulooze et al. 2016), upon which a recent IMI initiative
focusing on pain biomarkers has been proposed (Innovative Medicines
Initative 2016).
Innovative strategies are needed to identify novel biomarkers. In
this context, metabolomics represents an attractive molecular profiling
technology (Beger et al., 2016; Koen et al. 2016; Wishart 2016). The
metabolome comprises molecular intermediates and end-products
resulting from different cellular and physiological processes, encom-
passing a large diversity of small molecules that are closely related to
(patho)physiological conditions and treatment response phenotypes
(Fiehn 2002; Patti et al. 2012; Ramautar et al. 2013).
The current impact of metabolomics biomarkers in daily clinical
practice is still limited, which is probably associated with the specific
challenges encountered in clinical metabolomics, namely, study design,
bioanalysis and data analysis, that still need to be overcome (Kohler
et al. 2016). Guidelines addressing some of these challenges have been
already proposed and discussed elsewhere (Beger et al., 2016; Dunn
et al. 2011; Dunn et al. 2012; Kohler et al. 2016; Sumner et al. 2007;
Want et al. 2010). However, limited attention has been given to the
challenges associated with discovery of treatment individualization
biomarkers that would include explicit consideration of the disease
progression dynamics and drug-exposure response relationships. Inte-
grating established PK-PD and QSP concepts as well as techniques to
support the discovery of clinical metabolomics-based static prognostic
and dynamical disease treatment individualization biomarkers can
represent a powerful and relevant approach to bridge the gap between
current metabolomics practices and development of effective treatment
individualization biomarkers, as emphasized in Fig. 2. This review
provides practical considerations for development of metabolomics-
based treatment individualization biomarkers to enable precision
medicine. We focus specifically on the characterization of dynamic
biomarkers that describe disease progression and treatment response,
and static prognostic biomarkers that predict a clinical response
(Fig. 1).
2. Clinical Study Design and Bioanalytical Metabolomics
Strategies
This section discusses specific considerations for controlling and
reducing variation through appropriate study design and adequate
bioanalytical experiments to obtain high-quality metabolomics data as
well as optimize conditions for identification of the most relevant
treatment individualization biomarkers.
2.1. Prospective and retrospective studies
Metabolomics biomarker discovery studies are ideally based on
prospectively designed studies with a clear defined clinical response
outcome, although there is also significant value in the analysis of
archived samples from well-designed and previously conducted studies.
Retrospective studies either consist of short-term clinical studies that
may have been already designed to investigate a disease or treatment of
interest, or epidemiological studies. Epidemiological studies that collect
patient-derived samples (e.g., blood, urine, etc.) together with other
health data are relevant for the identification of disease progression
biomarkers (Hofman et al. 2015; Marmot and Brunner 2005; Pardo
et al. 2005; Salomaa 2016).
Fig. 1. Biomarkers discovery for drug treatment individualization. This schematic representation illustrates the role of metabolomics in combination with pharmacological PK-PD
and QSP modeling in biomarker discovery. The importance of prognostic and dynamic biomarkers, which can be used to respectively predict and describe the inter-individual variation in
disease progression and treatment response, is highlighted. PD, pharmacodynamics; PK, pharmacokinetics; QSP, quantitative systems pharmacology.
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2.2. Dichotomic and time course biomarkers
The majority of clinical metabolomics studies intended for biomar-
ker discovery are case-control studies aiming to identify differences
between the metabolite signatures of groups of patients (e.g., healthy
vs. diseased). However, such categorizations are often inappropriate
oversimplifications, especially for treatment individualization biomar-
kers, because disease and treatment response are inherently dynamic
processes. Moreover, metabolic profiles are associated with intra-
individual variability, resulting in convolution of intra- and inter-
individual variation in metabolic signatures. Therefore, collection of
repeated samples is of great importance for both static prognostic and
dynamical biomarkers to separate intra- from inter-individual variation.
Additionally, discretization of clinical outcome markers should be
prevented, since longitudinal and continuous clinical biomarkers con-
tain more information (e.g., disease severity scores). Fortunately, some
of these considerations are being increasingly recognized (Nagele et al.
2016; Poldrack et al. 2015; Sengupta et al. 2016).
2.3. Patient-specific factors introducing variability
Multiple patient-specific factors may influence the metabolome, and
thus need to be controlled in the design phase to minimize variation.
Patient-specific factors that may affect inter-individual variation in
response and metabolome include demographics (e.g., gender, age,
body weight), comorbidities, and concomitant medications (Beisken
et al. 2015; Dunn et al. 2012; Emwas et al. 2015). Patient-specific
characteristics may vary not only between but also within patients over
short periods of time; and include for instance circadian rhythms
(Giskeodegard et al. 2015) or the menstrual cycle (Wallace et al.
2010). Diet and changes in bodyweight may also influence the
metabolome (Scalbert et al. 2014). To this end, appropriate selection
criteria for patients should be used and adequately recorded.
2.4. Characterizing disease progression and treatment response
Treatment individualization biomarkers are ultimately developed to
provide insight into the inter-individual variability of disease progres-
sion dynamics and drug treatment response. Characterization of the
dynamics and exposure-response relationships of novel metabolomic
biomarkers is therefore essential. In order to assess disease progression,
epidemiological biobanking cohort studies are of relevance, combined
with appropriate focus on specific disease stages or stratification across
baseline disease states. For exposure-response relationships, informa-
tion on drug exposure in individual patients is essential, i.e., plasma
drug concentrations or by individual patient dosing histories (amount,
timing). Secondly, sufficiently spread or prospective stratification of
drug exposure and/or dose regimens is needed to allow characteriza-
tion of the exposure-response relationship.
2.5. Sampling sites
Body fluids such as blood or urine are commonly used for
identification of biomarkers. Blood-derived samples are usually pre-
ferred because of a relatively lower daily variation in the blood
metabolome compared to the urine and the on-demand availability in
patients. Blood-based metabolomics primarily provides information on
the extracellular metabolome, or the intracellular metabolome when
relevant (e.g., peripheral blood mononuclear cells). Depending on the
disease type, blood may sometimes be insufficient to reflect the disease
progression. For instance, in some central nervous system conditions,
other sample types such as cerebrospinal fluid may be needed to gather
Fig. 2. Illustration of the workflow for developing metabolomics-based treatment individualization biomarkers.
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complementary information (Mehta and Adler 2016).
2.6. Sample collection, preparation and storage
Variability in metabolic profiles can be affected by sample prepara-
tion and storage conditions. Rapid inhibition of enzymatic activity
(quenching) is particularly important for processing plasma or serum
samples because of the high concentration of still active enzymes after
collection (Kohler et al. 2016). Samples stored at −80 °C generally
present rather stable metabolome for at least 6 months, although some
metabolite classes may be sensitive to chemical and enzymatic reac-
tions during storage (Kanani et al. 2008; Vigor et al. 2014). Multiple
freeze-thaw cycles can lead to significant changes in the metabolome,
stressing the relevance of direct post-collection aliquoting (Kohler et al.
2016).
2.7. Sample size
The required sample size for treatment individualization biomarker
studies depends on several factors including the metabolic baseline
concentrations and expected changes thereof, sampling design, and
patient heterogeneity. Many of these factors may be uncertain for
metabolomics studies, and it is often unclear which particular metabo-
lite candidates will be of interest. Therefore, conducting metabolomics
studies following a two-stage design is recommended for obtaining
initial estimates of variability (Lenth 2001; Hyotylainen and Oresic
2016; Lenth 2007). Power analyses of prognostic or dynamic metabolic
biomarker studies are complex if accounting for repeated measure-
ments and multivariate metabolite profiles. Hierarchical simulation
analyses offer a practical approach to evaluate different study designs.
Additionally, the increasing public availability of metabolomics cohort
studies in healthy and diseased patient populations is of great relevance
to support efficient design methodologies. Historically, clinical meta-
bolomics studies have led to successful discriminatory identification of
metabolite profiles including approximately 30–50 subjects per group,
based on case control or time course studies, although these numbers
are dependent on design details and should be increased if various
factors in the study design are expected to influence the metabolic
variation.
2.8. Sampling times
For dynamic biomarker studies, the selection of sampling time
points within individuals is dependent on key aspects such as: i) the
expected time course of disease progression and the time of therapeutic
interventions to affect this progression; ii) whether the objective is to
study, for instance, early stage response to therapeutics or rather the
response during a long-term treatment scenario; and iii) whether
metabolomic sampling is combined with repeated PK sampling to
characterize also the drug concentration time course. Finally, even
though prognostic biomarkers are static, inclusion of multiple samples
remains essential to discriminate between intra- and inter-individual
variations in the blood metabolome.
2.9. Bioanalytical strategies for metabolomics
Nuclear magnetic resonance spectroscopy and mass spectrometry
(MS)-based techniques, especially in combination with chromatogra-
phy, are the major analytical platforms for clinical metabolomics.
Unique advantages and limitations of such state-of-the art techniques
have been already discussed elsewhere (Kohler et al. 2016; Wishart
2016). Both techniques can be used for untargeted or targeted
approaches.
Untargeted metabolomics strategies cover a large part of the
molecular metabolite space and allow for potential identification of
compounds that may not have been previously identified. However,
untargeted strategies do not directly identify molecular structures but
rather “features” typically defined by a retention time, mass-to-charge
ratio, and signal intensity. Moreover, untargeted strategies usually only
result in relative or semi-quantitative data.
Targeted approaches provide absolute concentrations for a set of
metabolites with known molecular structures. Targeted platforms cover
classes of metabolites with related molecular structures and which have
often known associations with (patho)physiological and drug response
processes. Examples are acylcarnitines in atherosclerosis, branched-
chain amino acids in diabetes, or phosphocholines and acylcarnitines in
Alzheimer's disease (Wishart 2016). If the set of metabolites of potential
interest have widely different physico-chemical properties, multiple
targeted platforms are necessary, thereby lowering throughput and
increasing costs.
In clinical metabolomics biomarker discovery, ultimately quantita-
tive data that are chemically and biologically interpretable is of great
importance, making targeted metabolomic platforms preferable.
However, available knowledge with respect to metabolite classes of
interest often remains insufficient. Therefore, two-stage strategies using
initial untargeted screening followed by quantitation, or a combination
of targeted approaches represent the most adequate solution to such
challenge.
2.10. Experimental validation of clinical biomarkers
The use of relevant experimental disease models (i.e., in vitro, in
vivo) in conjunction with metabolomics analyses may inform the
selection of targeted metabolomics platforms (Fig. 2). Moreover, in
parallel to or subsequent to clinical metabolomics biomarker discovery,
conduct of such experiments can be of great value to increase the
biological and mechanistic understanding of identified clinical meta-
bolomics-based biomarkers, and may support identification of transla-
tionally relevant metabolomic biomarkers. Particularly, recent devel-
opments in the field of human induced pluripotent stem cell derived cell
lines and 3D cell culture in combination with metabolomics may be of
significant value for establishing a close link between experimental
model systems and clinical biomarker studies.
2.11. Clinical validation of biomarkers
Clinical validation of metabolomics-based biomarkers represents
the last but crucial step of biomarker development, aiming to confirm
the clinical utility of the biomarkers candidate in treatment individua-
lization. These studies aim to evaluate the clinical relevance of
biomarkers candidates under conditions where patient and environ-
mental differences result in increased variability in the metabolome
(Lin et al. 2009). Consensus in best-practices for the conduct of such
studies in the context of metabolomics are still lacking, although will
generally follow validation studies for any other type of biomarker
(Mandrekar and Sargent 2009).
3. Multivariate and PK-PD Data Analysis
3.1. Challenges associated with metabolomics treatment individualization
biomarkers
The majority of clinical metabolomics studies aiming for treatment
individualization have been focusing on the determination of metabolic
signatures (i.e., a panel of metabolites) that discriminate between
discretized patient groups or predict a therapeutic response. These
signatures can be identified using various multivariate statistical
regression and classification techniques, e.g., partial least squares
regression, random forests. Such metabolite signatures are generally
considered to have better predictive performance than single molecule
profiles (Beger et al., 2016). Extensive external- or cross-validation
procedures during the data analysis process are important to prevent
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overfitting and determine metabolic signatures with high significance.
Conventional metabolic signatures do typically not consider patient-
specific factors that may introduce variation in the metabolome.
Moreover, they often do not take into account the intrinsically dynamic
nature of disease progression and treatment exposure-response re-
sponse relationships. Not correcting or considering these factors also
results in a reduced statistical power or bias. Most importantly, these
considerations are of critical importance to enable treatment indivi-
dualization biomarkers that may inform dose regimen optimization.
3.2. Mathematical PK-PD modeling concepts of relevance for metabolomics
biomarker discovery
The field of mathematical PK-PD modeling makes use of dynamical
compartmental modeling to characterize the dynamics of drug exposure
in relation to a biomarker describing the drug effect (Cleton et al. 1999;
Danhof et al. 2007; Dayneka et al. 1993) or disease progression (Chan
and Holford 2001; Danhof 2015; Schmidt et al. 2010). The resulting
dynamical model parameters then describe the shape of time course
profiles using a limited set of model parameters. It is worth mentioning
that although availability of PK data is the golden standard to quantify
exposure, individual drug dosing regimens may also be used as
surrogate exposure marker through the use of kinetic-PD modeling
approaches (Jacqmin et al. 2007).
Clinical PK-PD models are typically combined with statistical mixed
effect models to estimate inter-individual variability. The combination
of dynamical modeling, as highlighted in Fig. 3, allows obtaining
insight into inter-individual variation for different aspects of biomarker
dynamics and drug response, e.g., dose-response slope, maximum drug
effect, recovery half-life, resistance development, or rate of disease
progression, and their potential association with any prognostic pre-
dictor. Combined with the practical considerations described in Section
2, we consider the use of these PK-PD modeling approaches also of
major relevance to enable development of meaningful and appropriate
metabolomics-based treatment individualization biomarkers.
3.3. Metabolomics prognostic biomarkers
Prognostic (static) treatment individualization biomarkers typically
reflect some aspects of the “physiological state” of a patient that relates
to the (expected) drug treatment response or disease progression
dynamics. If continuous clinical time course data for treatment response
or drug treatment are available, dynamical models can be implemented
to capture the variability in different dynamical response character-
istics, e.g., maximum drug effect, rate of disease progression. The
individual estimates for these dynamical characteristics can then be
used to identify patient-specific predictors including metabolic prog-
nostic biomarkers (signatures) that predict a specific characteristic of
the clinical response. Standard multivariate regression techniques can
be used for this purpose (Valitalo et al. 2016). This approach allows for
straightforward integration with dose regimens and derivation of dose
adaptation, given the PK-PD framework used.
Fig. 3. Combination of metabolomics-based time course data with dynamical modeling. Dynamical mixed effect modeling of can be used to summarize a specific pharmacological
effect or an effect on disease progression. The distributions of pharmacological parameters (i.e., half maximum effect concentration, EC50, or effect half-life, Et-half) can be used to identify
metabolites associated with pharmacological response. Such distributions can also help in identifying relevant metabolites that can predict variation in the pharmacological response
between patients.
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3.4. Metabolomics dynamical disease progression and treatment response
biomarkers
Time course (or longitudinal) metabolic profiles aiming at identify-
ing dynamical disease progression and treatment response biomarkers
can be analyzed using dynamical and mixed effect modeling ap-
proaches to summarize longitudinal profiles for each metabolite into
a more relevant set of parameters, individually estimated for each
patient (Fig. 3). These individual summary parameters can then be
evaluated alone or in combination using statistical modeling ap-
proaches such as time-to-event- or logistic regression models, to predict
available clinical endpoint (e.g., time of death). This approach high-
lights a major advantage compared to the use of non-parametric
analysis approaches described for metabolomics (Nagele et al. 2016).
Alternatively, multivariate analysis approaches can be also used first for
metabolomics-based datasets of individual patients prior to applying a
dynamical characterization (Rasmussen et al. 2010). This has been
recently illustrated by van den Brink et al. who demonstrated the
relevance of metabolomics combined with PK-PD based selection and
analysis of multiplex hormonal data (van den Brink et al. 2016).
3.5. Multicompartimental dynamical systems pharmacology modeling
A mechanistic systems pharmacology extension of the previous
section may be envisioned where multi-compartmental dynamical
models are derived to describe dynamical associations between multi-
ple metabolomic biomarkers, rather than characterizing each metabo-
lite individually. To this end, as a first step, time course data allows to
obtain insight into the underlying network topology of metabolite
biomarkers, for instance using Bayesian network analysis (Yazdani
et al. 2016). Subsequently, metabolites that have shown relevant
clinical associations may be selected, and a reduced dynamical model
can be defined and fitted to metabolomic time course data using mixed
effect dynamical modeling approaches. Inclusion of relevant biological
variation (e.g., circadian rhythms) is also straightforward using this
approach (Jacobs et al. 2016; Mochel et al. 2013). In parallel, to
support development of such models, a deeper biological understanding
may be obtained by using enrichment analysis strategies that identify
statistical overrepresentation of metabolites with known biomolecular
pathway associations (Chagoyen and Pazos 2011). Finally, the transla-
tional value and parametrization of these models can potentially be
supported by integrative approaches that combine clinical samples with
experimental models.
4. Summary
Clinical metabolomics represents a powerful bioanalytical strategy
to identify novel treatment individualization biomarkers for response
prediction or dynamical description of both disease progression and
treatment response. Integration of clinical metabolomics with pharma-
cological considerations during may allow for derivation of more
clinically and pharmacologically meaningful biomarkers for treatment
individualization, eventually enabling personalized medicine. The
successful integration of metabolomics with pharmacological concepts
and modeling is dependent on explicit consideration of study designs
and data analysis techniques that can effectively quantify sources of
biological and pharmacological variability.
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